NICE (Multiple) Technology Appraisal Guidance No 118
Bevacizumab and cetuximab for the treatment of metastatic
colorectal cancer
NICE (Multiple) Technology Appraisal Guidance No 118 –
Bevacizumab and cetuximab for the treatment of metastatic
colorectal cancer
The above NICE appraisals have been considered by NHS Quality
Improvement Scotland through its revised procedure of processing of
NICE appraisals
Web reference for appraisal and other relate documents:
http://www.nice.org.uk/guidance/TA118
NHSScotland should note that:
- No important differences were identified for these NICE
appraisals and NHS Quality Improvement Scotland advises that the
recommendations are as valid for Scotland as for England and
Wales.
- NHSScotland should take account of the NICE appraisals and this
NHS Quality Improvement Scotland email in its planning, funding and
provision of services to ensure that recommended drugs or
treatments are made available to meet clinical need.
- NHS Quality Improvement Scotland advice represents the
evidence-based view of NHS Quality Improvement Scotland.
- This advice does not override or replace the individual
responsibility of health professionals to make appropriate
decisions in the circumstances of their individual patients, in
consultation with the patient and/or guardian or carer.
- No other publications on the NICE appraisal will be issued by
NHS Quality Improvement Scotland.
- Copies of the NICE appraisals can be downloaded from http://www.nice.org.uk/. Also on the
website are tools (a costing template and audit criteria) that NICE
has developed to help organisations to implement this guidance.
Finally, an easy to read summary of the appraisal, called
"understanding NICE guidance" is published on the NICE website to
provide information for patients and the public.
- Hard copies of the NICE appraisals are available from NHS
Quality Improvement Scotland (contact Shonagh Buchanan, tel 0141
225 6993 or email shonagh.buchanan@nhshealthquality.org)
Published Date: 24 January 2007
